NCT00131352.

Trial name or title	A study of the safety and efficacy of Synvisc in patients with symptomatic osteoarthritis of the knee
Methods
Participants	Country: Belgium (4 sites), Czech Republic (4 sites), France (5 sites), Germany (1 site), Netherlands (2 sites), United Kingdom (5 sites) Duration: 26 wk with possible repeat treatment after this time Inclusion criteria: age 40 years and above, pts with symptomatic OA pain of the knee Exclusion criteria: Pts with current or prior conditions or treatment that would impede measurement of efficacy or safety
Interventions	Hylan G‐F 20 Placebo
Outcomes	Pain relief
Starting date	May 2005
Contact information	David Perkins Study Director Genzyme
Notes	Sponsored by Genzyme. ClinicalTrialsgov. Identifier: NCT00131352 Expected completion: December 2006